Versant Venture Management, LLC Aligos Therapeutics, Inc. Transaction History

Versant Venture Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$0.35 - $1.07 $301,855 - $922,815	-862,444 Reduced 37.17%	1,457,937 $510,000
Q2 2021 Aug 12, 2021	SELL	$20.3 - $33.6 $19.7 Million - $32.7 Million	-971,958 Reduced 29.52%	2,320,381 $47.3 Million
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $43.5 Million - $108 Million	3,292,339 New	3,292,339 $91 Million

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Versant Venture Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Versant Venture Management, LLC with notifications on news.